Viatris Inc. and Alkermes plc: A Comprehensive Revenue Analysis

Pharma Giants' Revenue Journey: 2014-2023

__timestamp	Alkermes plc	Viatris Inc.
Wednesday, January 1, 2014	618789000	7719600000
Thursday, January 1, 2015	628335000	9429300000
Friday, January 1, 2016	745694000	11076900000
Sunday, January 1, 2017	903374000	11907700000
Monday, January 1, 2018	1094274000	11433900000
Tuesday, January 1, 2019	1170947000	11500500000
Wednesday, January 1, 2020	1038756000	11946000000
Friday, January 1, 2021	1173751000	17886300000
Saturday, January 1, 2022	1111795000	16262700000
Sunday, January 1, 2023	1663405000	15426900000
Monday, January 1, 2024	1557632000

Unlocking the unknown

A Tale of Two Companies: Viatris Inc. and Alkermes plc

In the ever-evolving pharmaceutical landscape, Viatris Inc. and Alkermes plc have carved distinct paths over the past decade. From 2014 to 2023, Viatris Inc. consistently outperformed Alkermes plc in revenue, showcasing a robust growth trajectory. In 2021, Viatris Inc. reached its peak, with revenues soaring to nearly 18 billion, marking a 130% increase from 2014. Meanwhile, Alkermes plc experienced a steady climb, culminating in a 169% rise in revenue by 2023, compared to its 2014 figures.

Key Insights

Viatris Inc.: Witnessed a significant revenue surge in 2021, reflecting strategic expansions and market penetration.
Alkermes plc: Demonstrated consistent growth, with a notable revenue spike in 2023, indicating successful product launches and market strategies.

This analysis underscores the dynamic nature of the pharmaceutical industry, where strategic decisions and market adaptability define success.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025